Company Analysis
Sign in

Enlivex Ltd. (ENLV)

Nasdaq: ENLV · Pharmaceutical Preparations · Tel Aviv · filing with the SEC since 2014
Full chart Alerts Compare
Grade4.8
◀ Past 5.1● Present 5.7▶ Future 3.8
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income$1.24B+8329.2%
Earnings per share$25.48+3590.4%
Operating cash flow-$10.4M+19.9%
Cash$1.9M-42.6%
Debtn/a
Shareholders’ equity$1.93B+8102.8%
Shares, diluted48.5M+136.4%
Return on equity63.8%
The recordfrom its filings
Filings in 202657
Newest filingNov 2 · 6-K
Annual reportMar 25, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted19
Filer categoryNon-accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton ENLV · research, not advice